The prestigious Revista de la Sociedad Española de Medicina Estética (SEME) has published, in its issue no. 83 (2025), a multicentre clinical study that supports the efficacy and safety of injectable polydioxanone (PDO), specifically ULTRACOL 200, distributed by IT Pharma for aesthetic medical treatments.
Practice-based clinical research
The article, titled “Injectable polydioxanone: efficacy and safety evaluation in aesthetic medicine”, was authored by Dr. Roberto Pedrero, Dr. Jesús Román Martínez, and Dr. Paloma Tejero. The study was based on a comprehensive survey conducted among 84 Spanish-speaking aesthetic doctors from Spain, Mexico, Chile, and Ecuador, all of them with hands-on experience in the clinical use of Ultracol.
The questionnaire was designed to collect data across three key areas: sociodemographic information and professional background; perception of the safety, efficacy, and satisfaction with injectable PDO; and the presence of adverse effects, whether immediate or delayed.
One of the study’s most relevant findings is that 90% of the participating doctors rated Ultracol as safe, effective, and easy to apply, with cannula being the most commonly used application technique.
Key study results
Results were evaluated using a scoring scale from 1 to 5. The most significant ratings were:
- Product safety: 4.7
- Improvement in skin quality: 4.3
- Professional satisfaction: 4.1
It is worth noting that doctors with more than 10 years of experience gave even higher ratings for treatment efficacy, reinforcing the value of Ultracol in expert hands.
High clinical safety
The study also highlights the excellent safety profile of the product. No serious adverse events were reported. Minor and temporary reactions such as erythema, bruising, or mild swelling were the only side effects observed. In fact, 73% of physicians reported no adverse effects at all.
0% serious adverse reactions.
Ultracol and innovation in biostimulation
Ultracol is the first and only collagen stimulator formulated with polydioxanone (PDO) in the form of microspheres, a biodegradable and biocompatible material. A single vial is equivalent to more than 1,000 monofilament threads (29G 38 50)
Thanks to its ability to stimulate the synthesis of collagen types I and III, Ultracol improves the skin’s firmness, elasticity, and texture. Its controlled biodegradation process, which completes in approximately six months, allows for long-lasting, visible results with no residue left in the tissue.
Its presentation in lyophilised vials allows for flexible and personalised reconstitution according to treatment needs. It is indicated for use on the face, neck, neckline, and body areas, including mobile zones where progressive structural improvement is desired without excessive volume.
Study conclusion
The study published by SEME supports the use of Ultracol as a benchmark injectable PDO in aesthetic medicine, highlighting its clinical efficacy, safety in real-world practice, and high levels of satisfaction among both practitioners and patients.
Read the full article in SEME Journal No. 83: www.seme.org/revista
